Oramed Pharmaceuticals Inc.
ORMP
A
|
$2.35
16K
|
Health Technology
(0.0% 1d) (-14.9% 1m) (7.3% 1y) (0.0% 2d) (0.9% 3d) (3.5% 7d) (-47.87% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 95,220,026
http://www.oramed.com
Sec Filling | Patents | 12 employees
(US) Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
insulin diabetes diabetic treatment injection
add to watch list Paper trade email alert is off
Press-releases
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Published: 2024-03-19 (Crawled : 13:00) - globenewswire.com
SCLX | $0.9091 -6.92% 430K
|
|
| O: -0.73%
H: 4.41%
C: -0.74%
ORMP A | $2.35 16K
|
Health Technology
|
| O: -1.07%
H: 4.68%
C: 1.8%
company payment innovation growth
PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization
Published: 2023-10-24 (Crawled : 12:30) - prnewswire.com
ORMP A | $2.35 16K
|
Health Technology
|
| O: -1.55%
H: 3.16%
C: 1.05%
trial
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Published: 2023-09-22 (Crawled : 20:00) - biospace.com/
SCLX | $0.9091 -6.92% 430K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.015 56K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP A | $2.35 16K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
Published: 2023-09-21 (Crawled : 00:00) - oramed.com
SCLX | $0.9091 -6.92% 430K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
ORMP A | $2.35 16K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Published: 2023-09-21 (Crawled : 20:00) - globenewswire.com
SCLX | $0.9091 -6.92% 430K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.015 56K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP A | $2.35 16K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Published: 2023-09-13 (Crawled : 13:00) - globenewswire.com
SCLX | $0.9091 -6.92% 430K
|
|
| O: 1.23%
H: 0.0%
C: -9.72%
SRNE | $0.015 56K
|
Health Technology
|
| O: -6.99%
H: 39.83%
C: 33.53%
ORMP A | $2.35 16K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: -6.17%
Oramed to Present at the 83rd American Diabetes Association Conference
Published: 2023-06-20 (Crawled : 13:00) - biospace.com/
ORMP A | $2.35 16K
|
Health Technology
|
| O: -0.52%
H: 4.7%
C: 4.18%
conference association diabetes
Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth
Published: 2023-05-23 (Crawled : 02:00) - prnewswire.com
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: 0.7%
H: 1.22%
C: -0.67%
NVO | News | $125.705 -2.28% 1.3M
|
Health Technology
|
| O: -1.39%
H: 0.06%
C: -2.77%
JNJ | News | $148.22 -0.9% 3.3M
|
Health Technology
|
| O: 0.15%
H: 0.74%
C: -0.18%
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: -0.25%
H: 0.69%
C: -2.24%
ABT | News | $106.78 -0.75% 2M
|
Health Technology
|
| O: -0.88%
H: 0.17%
C: -1.45%
ORMP A | $2.35 16K
|
Health Technology
|
| O: 0.9%
H: 10.29%
C: 0.0%
AZN | News | $71.065 0.3% 3.2M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: -1.46%
report global protein therapeutics growth market
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
Published: 2023-05-18 (Crawled : 12:00) - biospace.com/
ORMP A | $2.35 16K
|
Health Technology
|
| O: 6.34%
H: 7.25%
C: 6.48%
obesity diabetes
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Published: 2023-05-15 (Crawled : 13:00) - prnewswire.com
ORMP A | $2.35 16K
|
Health Technology
|
| O: 6.71%
H: 32.12%
C: 3.64%
authorization chinese application trial china insulin
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001213900-24-034222 | 4 | 2024-04-19 | 2024-04-17 | Buy | A | 29800 | 29800 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Last 48 Hours Insiders Buying
MNSB P 310 | $15.805 -3.39% 14K
|
Finance
|
15:30
TPL P 3 | $585.24 -0.44% 8K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $11.97 -0.08% 61K
|
|
00:30
CTRN P 29000 | $22.1 -0.59% 19K
|
Retail Trade
|
22:00
CONN | $3.735 0.95% 21K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.56 -0.51% 420K
|
Finance
|
17:30
RMCF | $3.54 2.5K
|
Consumer Non-Durables
|
20:10